All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JAB-3068
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Jacobio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2020
Details:
Under the terms of the agreement, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 with AbbVie covering R&D expenses.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous squamous cell carcinoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The company will present preliminary safety, tolerability and pharmacokinetic/pharmacodynamic data from the dose-escalation stage of ARTISTRY-2, the ongoing phase 1/2 study evaluating ALKS 4230 administered subcutaneously (SC) either once-weekly or once-every-three-weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Updated data from the Phase 1b stage demonstrated that the combination of cavrotolimod and pembrolizumab continued to be well tolerated, with a confirmed overall response rate (ORR) of 21% (4/19 patients) according to RECIST v1.1 criteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Cavrotolimod, the company’s SNA-enabled TLR9 agonist, is being developed for the treatment of solid tumors, in combination with anti-programmed cell death 1 (PD-1) therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Data from the ongoing ARTISTRY-1 study showed encouraging single-agent activity of ALKS 4230 in melanoma and durable responses in multiple tumor types in combination with pembrolizumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The cavrotolimod pharmacodynamic profile corroborated the efficacy data, as increased serum cytokines/chemokines, activated immune cells, and tumor infiltration by immune cells were observed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ALKS 4230,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALKS 4230
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Safety and anti-tumor efficacy data from the ongoing phase 1/2 ARTISTRY-1 study, evaluating ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with refractory solid tumors, will be shared in a mini oral presentation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The KOL meeting will focus on company's preliminary Phase 1b efficacy and safety data for cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
The dose expansion stage is designed to assess the anti-tumor response rate of cavrotolimod plus checkpoint inhibitor treatment, the safety and tolerability of the combination, and drug pharmacodynamics and pharmacokinetics.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
